Johnson & Johnson (NYSE:JNJ – Free Report) – Investment analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Johnson & Johnson in a research note issued on Tuesday, June 25th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of $10.47 per share for the year, down from their prior forecast of $10.57. Cantor Fitzgerald currently has a “Overweight” rating and a $215.00 target price on the stock. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.63 per share.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.68 earnings per share.
Read Our Latest Report on Johnson & Johnson
Johnson & Johnson Stock Down 0.3 %
Shares of Johnson & Johnson stock opened at $146.81 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The business has a fifty day simple moving average of $148.13 and a 200 day simple moving average of $154.24. The stock has a market cap of $353.32 billion, a PE ratio of 9.15, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.38%. The ex-dividend date was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
Institutional Trading of Johnson & Johnson
Several institutional investors and hedge funds have recently bought and sold shares of JNJ. Norges Bank bought a new stake in Johnson & Johnson during the fourth quarter worth about $4,071,642,000. Wellington Management Group LLP raised its stake in Johnson & Johnson by 16.4% in the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after buying an additional 3,391,657 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock valued at $3,453,978,000 after buying an additional 3,139,499 shares during the period. Swedbank AB bought a new stake in Johnson & Johnson in the first quarter valued at approximately $331,178,000. Finally, International Assets Investment Management LLC raised its stake in Johnson & Johnson by 7,875.8% in the fourth quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after buying an additional 2,064,175 shares during the period. Institutional investors own 69.55% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More
- Five stocks we like better than Johnson & Johnson
- What Are Growth Stocks and Investing in Them
- Why Paychex Stock’s Dip is the Best Opportunity in Today’s Cycle
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Any Pullback in Tech May Signal a Rotation into These 3 Sectors
- What Are Trending Stocks? Trending Stocks Explained
- 3 Stocks to Watch: Oracle, Casey’s, FedEx Signal Big Gains
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.